Literature DB >> 8301117

Unique phenotype and distinct TCR V beta repertoire in human peripheral blood alpha beta TCR+, CD4-, and CD8- double negative T cells.

T Niehues1, B Gulwani-Akolkar, P N Akolkar, W Tax, J Silver.   

Abstract

TCR-alpha beta+ CD4- CD8- double-negative (DN) T cells represent a small, poorly defined T cell subset in human peripheral blood that has been postulated to be potentially autoreactive. To define some of the characteristics of this subset of T cells, DN cells and CD4+ and CD8+ single-positive (SP) cells were purified from the peripheral blood of six unrelated individuals by a combination of positive selection and depletion using mAb conjugated to immunomagnetic beads. Purified DN cells were found to be enriched in cells expressing HLA-DR and the NK cell marker, CD56, when compared to the SP population. Furthermore, in contrast to SP cells that express the adhesion marker CD44, DN cells were found to express very little, if any, CD44. When the V beta TCR repertoires of DN and SP (CD4+ and CD8+) cells, determined by quantitative (q) PCR, were compared all three populations were found to be considerably different. Furthermore, several V beta segments (V beta 11 and V beta 19) were consistently expressed at higher levels on DN cells than on SP cells. The TCR repertoires of both DN and SP cells were frequently characterized by dominance of one or more V beta segments that could in some instances be shown to be restricted to the CD45RO+ ("memory") population. However, differences in TCR repertoire between DN and SP cells were observed even when CD45RO+ cells were removed before qPCR analysis. These studies suggest that the TCR repertoires of DN and SP cells are determined by different selection mechanisms and that DN and SP cells are directed against different Ag.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8301117

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Immunophenotypic analysis of the TCR-Vbeta repertoire in 98 persistent expansions of CD3(+)/TCR-alphabeta(+) large granular lymphocytes: utility in assessing clonality and insights into the pathogenesis of the disease.

Authors:  M Lima; J Almeida; A H Santos; M dos Anjos Teixeira; M C Alguero; M L Queirós; A Balanzategui; B Justiça; M Gonzalez; J F San Miguel; A Orfão
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  Human TCR-alpha beta+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype.

Authors:  José C Crispín; George C Tsokos
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

3.  T-cell receptor Vbeta gene expression in experimental lupus nephritis.

Authors:  M Sutmuller; H J Baelde; S Ouellette; E De Heer; J A Bruijn
Journal:  Immunology       Date:  1998-09       Impact factor: 7.397

Review 4.  Liver immunology.

Authors:  Dimitrios P Bogdanos; Bin Gao; M Eric Gershwin
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

5.  alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10.

Authors:  K J Hammond; L D Poulton; L J Palmisano; P A Silveira; D I Godfrey; A G Baxter
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

6.  Cytotoxicity of fresh NK1.1+ T cell receptor alpha/beta+ thymocytes against a CD4+8+ thymocyte population associated with intact Fas antigen expression on the target.

Authors:  H Arase; N Arase; Y Kobayashi; Y Nishimura; S Yonehara; K Onoé
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

7.  Complete Multilineage CD4 Expression Defect Associated With Warts Due to an Inherited Homozygous CD4 Gene Mutation.

Authors:  Rosa Anita Fernandes; Martin Perez-Andres; Elena Blanco; Maria Jara-Acevedo; Ignacio Criado; Julia Almeida; Vitor Botafogo; Ines Coutinho; Artur Paiva; Jacques J M van Dongen; Alberto Orfao; Emilia Faria
Journal:  Front Immunol       Date:  2019-11-08       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.